Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 275, Issue 1 44-1, 1998, Pages

  Trueblood, Nathan ^a   Ramasamy, Ravichandran ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NONE   (United States)

Author keywords

Carbon 13 nuclear magnetic resonance; Glyceraldehyde 3 phosphate dehydrogenase; NADH NAD+

Indexed keywords

ALDEHYDE REDUCTASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CARDIOVASCULAR DISEASE; CITRIC ACID CYCLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; ENZYME SUBSTRATE; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOLYSIS; ISOLATED HEART; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT;

EID: 33750868990     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1998.275.1.h75     Document Type: Article

References (26)

1. Alexander, M. C., M. Lomanto, N. Nasrin, and C. Ramaika. Insulin stimulates glyceraldehyde-3-phosphate dehydrogenase gene expression through cis-acting DNA sequences. Proc. Natl. Acad. Sci. USA 85: 5092-5096, 1988.
2. American Diabetes Association. Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 16, Suppl. 2: 72-78, 1993.
3. Bone, A. J. Animal models of insulin-dependent diabetes mellitus. In: Textbook of Diabetes, edited by J. C. Pickup and G. Williams. Oxford, UK: Blackwell, 1991, p. 151-163.
4. 13C NMR study of glucose oxidation in the intact functioning rat heart following diabetes induced cardiomyopathy. J. Mol. Cell. Cardiol. 25: 1203-1213, 1993.
5. Chatham, J. C., and J. F. Forder. Metabolic compartmentation of lactate in the glucose-perfused rat heart. Am. J. Physiol. 270 (Heart Circ. Physiol. 39): H224-H229, 1996.
6. Chatham, J. C., and J. F. Forder. Relationship between cardiac function and substrate oxidation in hearts of diabetic rats. Am. J. Physiol. 273 (Heart Circ. Physiol. 42): H52-H58, 1997.
7. Crisa, L., J. P. Mordes, and A. A. Rossini. Autoimmune diabetes mellitus in the BB rat. Diabetes Metab. Rev. 8: 9-37, 1992.
8. Gerbitz, K. D., K. Gempel, and D. Brdiczka. Mitochondria and diabetes: genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes 45: 113-126, 1994.
9. Jeffrey, F. M. H., V. Diczku, A. D. Sherry, and C. R. Malloy. Substrate selection in the isolated working rat heart: effects of reperfusion, afterload and concentration. Basic Res. Cardiol. 90: 388-396, 1995.
10. 1H nuclear magnetic resonance analysis of glutamate in tissue extracts. Anal. Biochem. 249: 201-206, 1997.
11. Knecht, E., and E. Roche. The reduction-oxidation status may influence the degradation of glyceraldehyde-3-phosphate dehydrogenase. FEBS Lett. 206: 339-342, 1986.
12. 13C labeling in studies of metabolic regulation. Prog. NMR Spectrosc. 20: 337-383, 1988.
13. Lopaschuk, G. D., M. Saddik, R. Barr, L. Huang, C. C. Barker, and R. A. Muzyka. Effects of high levels of fatty acids on functional recovery of ischemic hearts from diabetic rats. Am. J. Physiol. 263 (Endocrinol. Metab. 26): E1046-E1053, 1992.
14. Lopaschuk, G. D., S. R. Wall, P. M. Olley, and N. J. Davies. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid induced ischemic injury independent of changes in long chain acylcarnitine. Circ. Res. 63: 1036-1043, 1988.
15. 13C NMR spectroscopy. FEBS Lett. 212: 58-62, 1987.
16. 13C NMR under non-steady-state conditions. Biochemistry 29: 6756-6761, 1990.
17. Mochizuki, S., and J. R. Neely. Control of glyceraldehyde-3-phosphate dehydrogenase in cardiac muscle. J. Mol. Cell. Cardiol. 11: 221-236, 1979.
18. Novotny, M. V., M. F. Yancey, R. Stuart, D. Wiesler, and R. G. Peterson. Inhibition of glycolytic enzymes by endogenous aldehydes: a possible relation to diabetic neuropathies. Biochim. Biophys. Acta 1226: 145-150, 1994.
19. Obrosova, I., A. Faller, E. Ostrow, and J. R. Williamson. Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor. Curr. Eye Res. 16: 34-43, 1997.
20. Ramasamy, R., P. J. Oates, and S. Schaefer. Aldose reductase inhibition protects diabetic and non-diabetic rat hearts from ischemic injury. Diabetes 46: 292-300, 1997.
21. Salway, J. G. Regulation of glycolysis and Krebs cycle. In: Metabolism at a Glance, edited by J. G. Salway. Oxford, UK: Blackwell, 1995, p. 66-69.
22. Schaefer, S., L. J. Carr, E. Prussel, and R. Ramasamy. Effects of glycogen depletion on ischemic injury in the isolated rat heart: insights into preconditioning. Am. J. Physiol. 268 (Heart Circ. Physiol. 37): H935-H944, 1995.
23. 13C NMR. Biochemistry 31: 4833-4837, 1992.
24. Surges, R., and P. J. Oates. Aldose reductase inhibitors: recent developments. Prog. Drug Res. 40: 99-161, 1993.
25. Vanoverschelde, J.-L. J., M. F. Janier, J. E. Bakke, D. R. Marshall, and S. R. Bergmann. Rate of glycolysis during ischemia determine extent of ischemic injury and functional recovery after reperfusion. Am. J. Physiol. 267 (Heart Circ. Physiol. 36): H1785-H1794, 1994.
26. Williamson, J. R., K. Chang, M. Frangos, K. S. Hasan, Y. Ido, T. Kawamura, J. R. Nyengaard, M. Van den Enden, C. Kilo, and R. G. Tilton. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813, 1993.